The local biotechnology industry is a sector with high added value that generates exports of more than US$216 million.
The secretary of Industry and Productive Development of the Nation, Jose Ignacio de Mendigurenheld a working meeting with biotech companies and startups nucleated in the Argentine Chamber of Biotechnology (CAB), to enhance the high added value of the sectorwhich generates exports for more than US$216 million.
The meeting was held at the plant of mAbxiencea leading company in the production of monoclonal antibodies that plans to triple its production capacity by March 2024.
De Mendiguren.jpg
Mendiguren was accompanied by the Chief of Staff of the Secretariat of Industry and Productive Development, Gabriel Vienni; the Undersecretary of Industry, Priscilla Makari; and the national directors of SME Financing, Francis Abramovichand SME Policy and Management, paul bercovich. Representatives of member companies of the CAB were also present at the meeting, together with the executive coordinator of the CAB and members of the company mAbxience.
“There are not many countries that produce biotechnologyand these companies brought together in a chamber, together, realize our potential as a countryraises the pride and self-esteem of Argentines,” stated Mendiguren, who highlighted that our country is one of the 12 nations around the world that produce vaccines.
De Mendiguren.jpg
Telam
For his part, the vice president of the CAB, Sebastián Bagó, pointed out that “currently the Chamber has 35 mature companies, 92 startups and 3 accelerators. These 35 companies represent US$726 million in billing, US$216 million in exportsmore than 18 thousand direct jobsmore than 650 people doing Investigation and development and they invest 4.6% of their turnover in R&D, which is more than triple the industrial average”.
“We are a economic growth engine and for our industry it is important to have promotion and support instruments, which is why this relationship with the Industry Secretariat so that we can exchange opinions and information”, highlighted the authority.
biotechnology.jpg
Finally, Mendiguren toured the plant of the biotechnological company that is dedicated to the development, manufacture and commercialization of biotechnological products for human medicine. Currently, it is in the stage of expansion with the purpose of triple its productive capacity for March 2024.
Source: Ambito
